Arvid Sjolander
Overview
Explore the profile of Arvid Sjolander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
164
Citations
2588
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sjolander A, Gabriel E
Epidemiology
. 2025 Jan;
36(2):227-236.
PMID: 39887118
Age-period-cohort models have a long history in epidemiology, social science, and econometrics. An important feature of these models is that they suffer from an inherent identifiability problem, due to the...
2.
Bosi A, Lund L, Mahalingasivam V, Mazhar F, Christiansen C, Sjolander A, et al.
Clin Kidney J
. 2025 Jan;
18(1):sfae338.
PMID: 39802588
Background: Knowledge of which medications may lead to acute kidney injury (AKI) is limited, relying mostly on spontaneous reporting in pharmacovigilance systems. We here conducted an exploratory drug-wide association study...
3.
Mahalingasivam V, Faucon A, Sjolander A, Bosi A, Gonzalez-Ortiz A, Lando S, et al.
JAMA Netw Open
. 2024 Dec;
7(12):e2450014.
PMID: 39724377
Importance: COVID-19 infection has been associated with acute kidney injury. However, its possible association with long-term kidney function is not well understood. Objective: To investigate whether kidney function decline accelerated...
4.
Andersson-Emad J, Thunholm A, Nash S, Evans M, Lind Af Hageby S, Arnlov J, et al.
BMC Nephrol
. 2024 Nov;
25(1):408.
PMID: 39538192
Background: Chronic kidney disease (CKD) is a global health problem affected by under-recognition and under-treatment in primary care settings. Electronic clinical decision support (CDS) triggering systems have the potential to...
5.
Gabriel E, Sachs M, Sjolander A
Biostatistics
. 2024 Nov;
26(1).
PMID: 39520322
In instrumental variable (IV) settings, such as imperfect randomized trials and observational studies with Mendelian randomization, one may encounter a continuous exposure, the causal effect of which is not of...
6.
Tang B, Sjolander A, Wastesson J, Maura G, Blotiere P, Szilcz M, et al.
EClinicalMedicine
. 2024 Oct;
73:102689.
PMID: 39429814
Background: The comparative effectiveness of glucagon-like peptide-1 (GLP-1) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes mellitus (T2DM) is...
7.
Ojalehto Lindfors E, Lopes De Oliveira T, Reynolds C, Zhan Y, Aslan A, Jylhava J, et al.
Diabetes Obes Metab
. 2024 Oct;
27(1):207-214.
PMID: 39382007
Aims: About 10%-30% of individuals with obesity are metabolically healthy, but the specific characteristics of the metabolically healthy obesity (MHO) phenotype remain unclear. We aimed to examine how physical activity,...
8.
9.
Huang T, Bosi A, Faucon A, Grams M, Sjolander A, Fu E, et al.
JAMA Intern Med
. 2024 Aug;
184(10):1195-1203.
PMID: 39133509
Importance: Hyperkalemia is a common complication in people with type 2 diabetes (T2D) that may limit the use of guideline-recommended renin-angiotensin system inhibitors (RASis). Emerging evidence suggests that glucagon-like peptide-1...
10.
Sjolander A, Gabriel E
Am J Epidemiol
. 2024 Aug;
PMID: 39103282
Recently, a bespoke instrumental variable method was proposed, which, under certain assumptions, can eliminate bias due to unmeasured confounding when estimating the causal exposure effect among the exposed. This method...